Helping interpret the Human Medicines (Amendment) Modular Manufacture and Point of Care regulations 2025.
Similar Posts
Guidance: The Innovative Devices Access Pathway (IDAP)
The Innovative Devices Access Pathway (IDAP) pilot is designed to accelerate the development of innovative medical devices that meet an unmet clinical need in the NHS and support their integration into the UK market.
Guidance: Timelines for acceptance of CE marked medical devices in Great Britain (GB)
Transitional arrangements and timelines for acceptance of CE marked medical device in Great Britain.
Medicines and Medical Devices Act 2021 – Stakeholder survey
We invite feedback on the operation and impact of the human medicines and medical devices legislation as part of a statutory review required under the Medicines and Medical Devices Act 2021.
MHRA approves imlunestrant tosylate (Inluryo) – a new treatment for breast cancer
As with any medicine, the MHRA will keep the safety and effectiveness of imlunestrant tosylate under close review.
Strengthening collaboration between the MHRA and the Department of Health Northern Ireland
The MHRA and Northern Ireland partners are working together to support innovation, enhance patient safety and ensure people in Northern Ireland benefit from world-class regulation.
MHRA statement on Pathways clinical trial
As with all clinical trials, the MHRA’s top priority is the safety and wellbeing of the trial participants.